目的:结核病(TB)仍然是一个全球性的公共卫生问题。由于缺乏将Ct值与临床评分相关的文献,医生无法清楚地将周期阈值(Ct)值解释为分枝杆菌负担的量度。这项研究旨在将临床评分参数(BandimTB评分和Karnofsky性能评分(KPS))与通过基于药筒的核酸扩增测试(CBNAAT)获得的Ct值相关联。
方法:该研究从2019年11月至2021年10月,共招募了40例病例。基于抗酸杆菌的Ziehl-Neelsen染色和/或GeneXpertMTB/RIF测定,将这些病例鉴定为肺结核患者。使用标准化问卷记录BandimTB评分和KPS。
结果:BandimTB评分与Ct值(平均值)之间存在很强的负相关,并且这种相关性具有统计学意义(rho=-0.82,p<0.001)。KPS与Ct值(平均值)呈中度正相关,并且这种相关性具有统计学意义(rho=0.57,p<0.001)。
结论:尚无文献将BandimTB评分和KPS与CBNAAT对肺结核的Ct值进行比较。因此,了解CBNAAT周期阈值的正确利用及其与临床评分参数的相关性,将有助于临床医师及早发现并及时开始适当的治疗.
OBJECTIVE: Tuberculosis (TB) continues to be a global public health problem. Physicians fail to clearly interpret cycle threshold (Ct) values as a measure of mycobacterial burden due to the paucity of literature correlating Ct values with the clinical scoring. This study aims to correlate the clinical scoring parameters (Bandim TB score and Karnofsky Performance score (KPS)) with Ct values obtained by Cartridge-Based Nucleic Acid Amplification Test (CBNAAT).
METHODS: The study spanned from November 2019 to October 2021, during which a total of 40 cases were recruited. These cases were identified as pulmonary TB patients based on Ziehl-Neelsen staining for acid-fast bacilli and/or the GeneXpert MTB/RIF assay. Bandim TB scores and KPSs were recorded using standardized questionnaires.
RESULTS: There was a strong negative correlation between Bandim TB score and Ct value (mean), and this correlation was statistically significant (rho = -0.82, p < 0.001). There was a moderate positive correlation between KPS and Ct value (mean), and this correlation was statistically significant (rho = 0.57, p < 0.001).
CONCLUSIONS: No literature has compared Bandim TB score and KPS with the Ct values obtained by CBNAAT for pulmonary TB. Thus, the knowledge on the proper utilization of CBNAAT cycle threshold values and its correlation with clinical scoring parameters will help clinicians in the early identification and prompt initiation of appropriate treatment.